Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 5Completed 5Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 63Sarcoma 22Lymphoid 19Genitourinary 17Other hematologic neoplasm 14Gynecologic 12Plasma cell 11Myeloid 11Dermatologic 10Breast 9Gastrointestinal 4Other solid neoplasm 2NET 2Endocrine 2Classical hematology 1

Conditions

Neuroendocrine Tumors 46Neoplasms 8Carcinoid Tumor 7Neoplasm Metastasis 5Gastro-enteropancreatic neuroendocrine tumor 5Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Serotonin Syndrome 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Neoplasms by Site 2Digestive System Neoplasms 2Digestive System Diseases 2Cholangiocarcinoma 2Carcinoma, Islet Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1

Interventions

pertuzumab 1gallium Ga 68 dotatate 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neuroblastoma × NET × Clear all
NCT02177773 2019-11-12

DOTA-TOC

University of California, San Francisco

Phase 1/2 Terminated
300 enrolled 5 charts
CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡